Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

Filter conferences

 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
      
      
 
      
 
      
      
      
      
      
      
      
      
      
      
2nd Gene Therapy for Blood Disorders

2nd Gene Therapy for Blood Disorders

Categories

Date of beginning

Tuesday, 09 March 2021

Duration

3 days

City

Online

Contact

Ellie Saunders

E-Mail

This email address is being protected from spambots. You need JavaScript enabled to view it.

Memo

There's currently a lot of exciting news circulating about the progress of genetic therapies targeting blood disorders. As more and more promising results emerge from various clinical 3 trials, it's essential that this industry comes together to share knowledge, optimize trial design and discuss strategies for commercial launch. The 2nd Gene Therapy for Blood Disorders is the only industry meeting specifically dedicated to overcoming the clinical and commercial challenges faced in gene therapy drug development for hemophilia, sickle cell disease, beta thalassemia and other blood disorders. Join the likes of UniQure, Graphite Bio, bluebird bio, Sanofi, Spark Therapeutics and more industry pioneers as they share their latest insights and lessons learned to help accelerate programs to market. URLs:Tickets: https://go.evvnt.com/698778-2?pid=5569 Brochure: https://go.evvnt.com/698778-3?pid=5569  Date and Time: On Tuesday March 09, 2021 at 8:00 am (ends Thursday March 11, 2021 at 6:00 pm) Prices:Conference Only Industry - Early Rate: USD 1499.00,Conference Only Industry - Standard Rate: USD 1999.00,Conference Only Academic - Early Rate: USD 1199.00,Conference Only Academic - Standard Rate: USD 1799.00 Speakers: Gabriela Denning, Vice President, Research and Development, Expression Therapeutics, Clark Paramore, Head of Value Demonstration, Vice President HEOR, bluebird bio, David Page, National Director of Health Policy, Canadian Hemophilia Society, Ian Winburn, Vice President, Global Medical Lead, Hemophilia, Endocrine and IEM, Rare Diseases, Pfizer, Julian Down, Senior Director, Gene Therapy, Poseida Therapeutics, Kate Zhang, Vice President, Editas Medicine, Lesha Shah, Assistant Professor, Medical Director, Child, Adolescent and Family Services, Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, John Pasi, Professor, Haemostasis and Thrombosis, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Mark Trusheim, Strategic Director, NEWDIGS and Visiting Scientist, MIT Sloan, Marcus Droege, Vice President and Head Global RWE, bluebird bio, Nick Li Senior Director, Health Economics and Outcomes Research, UniQure, Nicolas Garnier, Director, Patient Advocacy, Pfizer, Paul Monahan, Clinical Development Lead, Hematology, Spark Therapeutics, Richard McFarland, President, Standards Coordinating Body (SCB), Sandeep Soni, Executive Director, Clinical Development, CRISPR Therapeutics, Inc., Pablo Rendo, Global Project Head, Red Blood Disorders and Rare Disease Gene Therapy, Sanofi, Matthew Birmingham, Senior Director, Supply Chain, bluebird bio, Steven Arkin, Executive Director, Clinical Research, Rare Diseases Research Unit, Pfizer Worldwide R and D, Pfizer, Wendy Pang, Executive Director, Research and Clinical Development, Jasper Therapeutics